Epica International, a Landrum, SC-based leader in advanced medical imaging and precision robotics, has successfully secured an $18 million growth capital loan. This new funding will help the company expand its business and develop new technologies for healthcare and manufacturing.

Key Details of the Funding

The loan was provided by Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P., both of which are part of the Avenue Capital Group. The initial $13.5 million of the loan will be used to refinance Epica’s existing debt and support the company’s growth. This includes expanding its operations and accelerating research and development. An additional $4.5 million is available, depending on the achievement of specific performance milestones.

The loan agreement spans four years and also includes a provision for Avenue Capital to receive a 0.5% equity stake in Epica International. Avenue Capital also has the option to invest an additional $2 million in equity over the next two years. Additionally, Avenue can convert up to $3.5 million of their loan into common stock at a price of $8.50 per share.

Epica’s Role in Healthcare and Robotics

Epica International, led by CEO Joe Soto, is known for its advanced medical imaging and precision robotics technologies. These technologies are widely used in both human and animal healthcare, as well as in scientific research. Epica’s patented medical imaging tools enable clinicians to achieve higher accuracy, leading to better outcomes for patients. These tools are also helpful in research, allowing scientists to work with more precise data.

Epica’s robotics division focuses on creating robotic solutions that help streamline manufacturing processes. These robots enhance production quality by combining precision engineering with advanced automation, which leads to higher efficiency and accuracy in manufacturing. This technology is used across a range of industries, helping businesses improve their production lines.

Patents and Innovations

Epica International currently holds 75 patents, with more pending, for its innovative medical imaging and robotics platforms. These patents are recognized not only in the U.S. but also in the European Union and other countries. This intellectual property highlights the company’s commitment to leading in both the healthcare and robotics fields.

Future Plans

With this new funding, Epica is set to grow its impact in the medical imaging and robotics industries. The growth capital will enable the company to continue developing its cutting-edge technology and expand into new markets. The additional capital available through the loan will be used for further advancements as the company hits key milestones.

Epica’s innovations in both healthcare and industrial robotics are expected to revolutionize these sectors. By continuing to develop technologies that enhance accuracy and efficiency, the company is well-positioned to drive positive change in both human and animal healthcare, as well as in manufacturing processes.

For more information about Epica International’s groundbreaking technologies and future developments, visit their website.